journal article·2022-12-27Open access

Skin Vaccination with Ebola Virus Glycoprotein Using a Polyphosphazene-Based Microneedle Patch Protects Mice against Lethal Challenge

Andrey Romanyuk, Ruixue Wang, Alexander Marin, Benjamin M. Janus, Eric I. Felner, Dengning Xia, Yenny Goez-Gazi, Kendra J. Alfson, Abdul S. Yunus, Eric A. Toth, Gilad Ofek, Ricardo Carrion, Mark R. Prausnitz, Thomas R. Fuerst, Alexander K. Andrianov

Abstract

Ebolavirus (EBOV) infection in humans is a severe and often fatal disease, which demands effective interventional strategies for its prevention and treatment. The available vaccines, which are authorized under exceptional circumstances, use viral vector platforms and have serious disadvantages, such as difficulties in adapting to new virus variants, reliance on cold chain supply networks, and administration by hypodermic injection. Microneedle (MN) patches, which are made of an array of micron-scale, solid needles that painlessly penetrate into the upper layers of the skin and dissolve to deliver vaccines intradermally, simplify vaccination and can thereby increase vaccine access, especially in resource-constrained or emergency settings. The present study describes a novel MN technology, which combines EBOV glycoprotein (GP) antigen with a polyphosphazene-based immunoadjuvant and vaccine delivery system (poly[di(carboxylatophenoxy)phosphazene], PCPP). The protein-stabilizing effect of PCPP in the microfabrication process enabled preparation of a dissolvable EBOV GP MN patch vaccine with superior antigenicity compared to a non-polyphosphazene polymer-based analog. Intradermal immunization of mice with polyphosphazene-based MN patches induced strong, long-lasting antibody responses against EBOV GP, which was comparable to intramuscular injection. Moreover, mice vaccinated with the MN patches were completely protected against a lethal challenge using mouse-adapted EBOV and had no histologic lesions associated with ebolavirus disease.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Transgenic Plants and Applications · Poxvirus research and outbreaks

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA

Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA

Department of Pediatrics, Division of Endocrinology, Emory University School of Medicine, Atlanta, GA 30322, USA

School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China

Texas Biomedical Research Institute, San Antonio, TX 78227, USA

Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA

Funding

the University of Maryland Strategic Partnership

References (62)

Show source-provided references
1. Agent of disease contracted from green monkeys10.1126/science.160.3830.888 ↗
2. Centers for Disease Control and Prevention (2022, December 23). History of Ebola Virus Disease (EVD) Outbreaks, Available online: https://www.cdc.gov/vhf/ebola/history/chronology.html#anchor_1526565114626.
3. Recurrent Ebolavirus disease in the Democratic Republic of Congo: Update and challenges10.3934/publichealth.2019.4.502 ↗
4. Woolsey, C., and Geisbert, T.W. (2021). Current state of Ebola virus vaccines: A snapshot. PLoS Pathog., 17.10.1371/journal.ppat.1010078 ↗
5. Ebola virus disease: Current vaccine solutions10.1016/j.coi.2021.03.008 ↗
6. Recent developments and strategies of Ebola virus vaccines10.1016/j.coph.2021.06.008 ↗
7. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection10.1016/j.cell.2015.12.022 ↗
8. Cutaneous immunization: An evolving paradigm in influenza vaccines10.1517/17425247.2014.885947 ↗
9. Technology update: Dissolvable microneedle patches for vaccine delivery10.2147/MDER.S198220 ↗
10. Microneedle-Mediated Vaccination: Innovation and Translation10.1016/j.addr.2021.113919 ↗
11. Trends in drug- and vaccine-based dissolvable microneedle materials and methods of fabrication10.1016/j.ejpb.2022.02.013 ↗
12. Dissolving Microneedle Patches for Dermal Vaccination10.1007/s11095-017-2223-2 ↗
13. Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine10.1126/sciadv.abj8065 ↗
14. Nanoemulsion-based dissolving microneedle arrays for enhanced intradermal and transdermal delivery10.1007/s13346-021-01107-0 ↗
15. Bezbaruah, R., Chavda, V.P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., and Vora, L. (2022). Nanoparticle-Based Delivery Systems for Vaccines. Vaccines, 10.10.3390/vaccines10111946 ↗
16. Faizi, H.S., Vora, L.K., Nasiri, M.I., Wu, Y., Mishra, D., Anjani, Q.K., Paredes, A.J., Thakur, R.R.S., Minhas, M.U., and Donnelly, R.F. (2022). Deferasirox Nanosuspension Loaded Dissolving Microneedles for Intradermal Delivery. Pharmaceutics, 14.10.3390/pharmaceutics14122817 ↗
17. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): A randomised, partly blinded, placebo-controlled, phase 1 trial10.1016/S0140-6736(17)30575-5 ↗
18. Forster, A.H., Witham, K., Depelsenaire, A.C.I., Veitch, M., Wells, J.W., Wheatley, A., Pryor, M., Lickliter, J.D., Francis, B., and Rockman, S. (2020). Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. PLOS Med., 17.10.1371/journal.pmed.1003024 ↗
19. Trends of microneedle technology in the scientific literature, patents, clinical trials and internet activity10.1016/j.biomaterials.2020.120491 ↗
20. Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin10.1146/annurev-chembioeng-060816-101514 ↗
21. Potential use of microarray patches for vaccine delivery in low- and middle-income countries10.1016/j.vaccine.2019.03.035 ↗
22. Microneedle patches for vaccination in developing countries10.1016/j.jconrel.2015.11.019 ↗
23. The success of microneedle-mediated vaccine delivery into skin10.1080/21645515.2016.1171440 ↗
24. Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge10.1038/s41598-018-29135-w ↗
25. Microneedles for vaccine delivery: Challenges and future perspectives10.4155/tde-2017-0032 ↗
26. Transdermal immunomodulation: Principles, advances and perspectives10.1016/j.addr.2018.03.010 ↗
27. Depelsenaire, A.C.I., Witham, K., Veitch, M., Wells, J.W., Anderson, C.D., Lickliter, J.D., Rockman, S., Bodle, J., Treasure, P., and Hickling, J. (2021). Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial. PLoS ONE, 16.10.1371/journal.pone.0255282 ↗
28. Local Response to Microneedle-Based Influenza Immunization in the Skin10.1128/mBio.00012-12 ↗
29. Polyphosphazene immunoadjuvants: Historical perspective and recent advances10.1016/j.jconrel.2020.12.001 ↗
30. Andrianov, A.K. (2009). Polyphosphazenes for Biomedical Applications, John Wiley & Sons.10.1002/9780470478882 ↗
31. Andrianov, A.K., and Allcock, H. (2018). Polyphosphazenes in Biomedicine, Engineering & Pioneering Synthesis, American Chemical Society.10.1021/bk-2018-1298 ↗
32. Recent advances in experimental polyphosphazene adjuvants and their mechanisms of action10.1007/s00441-018-2929-4 ↗
33. Current research on respiratory viral infections: Fourth International Symposium10.1016/S0166-3542(02)00055-4 ↗
34. A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime with Oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 (CM235/SF2) Boost10.1097/QAI.0b013e3181354bd7 ↗
35. Safety and Immunogenicity of a randomized Phase I prime-boost trial with ALVAC-HIV (vCP205) and Oligomeric gp160 MN/LAI-2 Adjuvanted in Alum or Polyphosphazene10.1093/infdis/jiw059 ↗
36. The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells10.1016/j.biomaterials.2014.06.043 ↗
37. PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies10.1002/jps.22367 ↗
38. Protein stabilization in aqueous solutions of polyphosphazene polyelectrolyte and non-ionic surfactants10.1021/bm100603p ↗
39. Microneedles with Intrinsic Immunoadjuvant Properties: Microfabrication, Protein Stability, and Modulated Release10.1007/s11095-010-0133-7 ↗
40. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization10.1073/pnas.0908842106 ↗
41. Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop10.1038/s41467-018-06113-4 ↗
42. Synthesis and biologically relevant properties of polyphosphazene polyacids10.1021/bm049745d ↗
43. Dissolving microneedles for transdermal drug delivery10.1016/j.biomaterials.2007.12.048 ↗
44. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines10.1016/j.jconrel.2017.06.017 ↗
45. Skin Vaccination with Dissolvable Microneedle Patches Incorporating Influenza Neuraminidase and Flagellin Protein Nanoparticles Induces Broad Immune Protection against Multiple Influenza Viruses10.1021/acsabm.1c00240 ↗
46. Dissolving polymer microneedle patches for influenza vaccination10.1038/nm.2182 ↗
47. Dissolvable Microneedle Patches for the Delivery of Cell-Culture-Derived Influenza Vaccine Antigens10.1002/jps.23019 ↗
48. Lee, B.-M., Lee, C., Lahiji, S.F., Jung, U.-W., Chung, G., and Jung, H. (2020). Dissolving microneedles for rapid and painless local anesthesia. Pharmaceutics, 12.10.3390/pharmaceutics12040366 ↗
49. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate10.1073/pnas.2112008119 ↗
50. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells10.1128/JVI.01403-18 ↗
51. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein10.1128/JVI.02172-15 ↗
52. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site10.1016/j.celrep.2016.04.026 ↗
53. An overview on field-flow fractionation techniques and their applications in the separation and characterization of polymers10.1016/j.progpolymsci.2008.11.001 ↗
54. Molecular-Level Interactions of Polyphosphazene Immunoadjuvants and Their Potential Role in Antigen Presentation and Cell Stimulation10.1021/acs.biomac.6b01251 ↗
55. Cationic Fluoropolyphosphazenes: Synthesis and Assembly with Heparin as a Pathway to Hemocompatible Nanocoatings10.1021/acsabm.1c01099 ↗
56. Ebolavirus comparative genomics10.1093/femsre/fuv031 ↗
57. The pathology of experimental Ebola virus infection in monkeys10.1002/path.1711250303 ↗
58. Pathogenesis of Experimental Ebola Zaire Virus Infection in BALB/c Mice10.1053/jcpa.2001.0502 ↗
59. Ebola Virus Infection in Commonly Used Laboratory Mouse Strains10.1093/infdis/jiy208 ↗
60. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice10.1016/j.vaccine.2016.02.033 ↗
61. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses10.3389/fimmu.2021.703986 ↗
62. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability10.1016/j.cell.2017.04.038 ↗